The long-term perspective on the pharmaceutical heavyweight appears interesting!

Pfizer (PFE) could be interesting for long-term investors due to a combination of an attractive dividend, a strategic realignment after the COVID boom, and promising developments in the pipeline, even though the company is currently facing challenges. Following the peak of the COVID-19 pandemic, sales of COVID products (Comirnaty and Paxlovid) have significantly decreased, leading to a noticeable decline in overall revenues for the company. Pfizer responded with a radical restructuring and a focus on long-term, sustainable growth. A key focus is...